HILDEN, Germany, March 15, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Gold, the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, was selected by the Taiwan Centers for Disease Control (Taiwan CDC) to replace the tuberculin skin test for screening at-risk individuals five years and older.
Starting this month, Taiwan's nationwide TB control effort will use QuantiFERON-TB Gold to test close contacts of patients with active tuberculosis, a contagious and life-threatening disease. In addition to treating patients with active TB, Taiwan will provide antibiotic treatment for patients identified as having latent TB infection (which if untreated can remain dormant and be activated years later). Only children younger than five years of age will be screened with the skin test.
"We are pleased to partner with Taiwan in combatting TB in their screening programs which will now employ the world's most accurate test for latent TB infection, QuantiFERON-TB Gold. In addition to providing tests, QIAGEN will offer 25 training courses for public health nurses and medical technicians in all 22 counties," said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. "Around the world, QuantiFERON-TB technology has proven its value as an efficient, cost-effective testing solution to aid in TB control efforts. Screening at-risk populations for latent TB infection allows early treatment and prevention of the active disease, which is contagious and requires aggressive treatment with antibiotics."
Click here for full press release
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: email@example.com ir.qiagen.com
SOURCE QIAGEN N.V.